Answers are grounded in this paper and cite their sources.
Risk is a characteristic of innovative industries. The process of new product development in the biopharmaceutical sector is extremely dynamic and unpredictable, creating both risks and opportunities for the small and medium-sized enterprises. The survival and development of these firms is determined by their capacity to develop flexible, but effective responses to the challenges of the competitive environment. This study investigates the risk management procedures implemented by the UK biopharmaceutical SMEs, and the importance of flexibility for enhancing risk management in the new product development process. On the basis of the data collected and interpreted, the study proposes a multi-level model of flexible risk management approach for biopharmaceutical firms.
No takes yet. Share an insight, caveat, or question.
Gurǎu et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: